{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:22:28Z","timestamp":1787764948568,"version":"build-2784847793"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapies. Their mechanism promotes a cytotoxic T-cell activation against the tumor cells, but as a consequence, immune-mediated toxicities are increasingly being identified. Cutaneous immune-mediated adverse events (AE) occur in 32% of patients, with possible higher grade AEs seen with anti-programmed cell death protein 1, such as nivolumab. A 67-year-old woman with metastatic melanoma, previously treated for 2 years on dual ICI (ipilimumab and nivolumab), had her treatment interrupted due to grade-3 hepatitis. She was subsequently recommenced on single-agent nivolumab with good response, before discontinuation due to remission. She reported worsening scalp pruritus with associated erythema, scaling, and global hair thinning. On examination, she had significant erythema throughout the scalp with perifollicular scaling and evidence of scarring. She reported severe distress from her symptoms. Her scalp biopsy demonstrated features of scarring alopecia with infundibular and isthmic inflammation and interface change in keeping with lichen planopilaris. Follicular toxicities are rarely reported, possibly due to imprecise AE phenotyping or underreporting. However, growing evidence suggests that patients can develop follicular pigmentary changes and nonscarring alopecia. To our knowledge, this is the first case of scarring alopecia reported with nivolumab. Current treatments for ICI-induced toxicities are limited.<\/jats:p>","DOI":"10.4103\/ijt.ijt_95_21","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T07:00:09Z","timestamp":1701673209000},"page":"105-107","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Nivolumab-Induced Lichen Planopilaris: Case Report and Literature Review of Hair Disorders Associated with Targeted Oncological Therapies"],"prefix":"10.4103","volume":"15","author":[{"given":"Leila","family":"Asfour","sequence":"first","affiliation":[{"name":"The Dermatology Centre, Salford Royal NHS Foundation Trust, Salford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rutkowski","sequence":"additional","affiliation":[{"name":"The Dermatology Centre, Salford Royal NHS Foundation Trust, Salford, UK"},{"name":"Centre for Dermatology Research, University of Manchester, MAHSC and NIHR Manchester, Biomedical Research Centre, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iskander H.","family":"Chaudhry","sequence":"additional","affiliation":[{"name":"Department of Dermatopathology, Liverpool Clinical Laboratories, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Harries","sequence":"additional","affiliation":[{"name":"The Dermatology Centre, Salford Royal NHS Foundation Trust, Salford, UK"},{"name":"Centre for Dermatology Research, University of Manchester, MAHSC and NIHR Manchester, Biomedical Research Centre, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"R1-20240903","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R2-20240903","doi-asserted-by":"crossref","first-page":"284","DOI":"10.5021\/ad.2021.33.3.284","article-title":"Nivolumab-induced alopecia areata:A case report and literature review","volume":"33","author":"Kim","year":"2021","journal-title":"Ann Dermatol"},{"key":"R3-20240903","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jdcr.2018.05.022","article-title":"Nivolumab-induced alopecia areata:A reversible factor of good prognosis?","volume":"4","author":"Lakhmiri","year":"2018","journal-title":"JAAD Case Rep"},{"key":"R4-20240903","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"R5-20240903","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jdcr.2017.12.002","article-title":"Lichen planopilaris associated with pembrolizumab in a patient with metastatic melanoma","volume":"4","author":"Cogen","year":"2018","journal-title":"JAAD Case Rep"},{"key":"R6-20240903","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ad.2018.10.019","article-title":"Adverse Hair Reactions to New Targeted Therapies for Cancer","volume":"110","author":"Mir-Bonaf\u00e9","year":"2019","journal-title":"Actas Dermosifiliogr (Engl Ed)."},{"key":"R7-20240903","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/exd.14155","article-title":"Hair follicle immune privilege and its collapse in alopecia areata","volume":"29","author":"Bertolini","year":"2020","journal-title":"Exp Dermatol"},{"key":"R8-20240903","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/jid.2013.368","article-title":"Hair follicle mesenchyme-associated PD-L1 regulates T-cell activation induced apoptosis:A potential mechanism of immune privilege","volume":"134","author":"Wang","year":"2014","journal-title":"J Invest Dermatol"},{"key":"R9-20240903","doi-asserted-by":"crossref","first-page":"e94260","DOI":"10.1371\/journal.pone.0094260","article-title":"Abnormal interactions between perifollicular mast cells and CD8+T-cells may contribute to the pathogenesis of alopecia areata","volume":"9","author":"Bertolini","year":"2014","journal-title":"PLoS One"},{"key":"R10-20240903","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/path.4233","article-title":"Lichen planopilaris is characterized by immune privilege collapse of the hair follicle's epithelial stem cell niche","volume":"231","author":"Harries","year":"2013","journal-title":"J Pathol"},{"key":"R11-20240903","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3390\/cancers12030546","article-title":"Association of steroids use with survival in patients treated with immune checkpoint inhibitors:A systematic review and meta-analysis","volume":"12","author":"Petrelli","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R12-20240903","doi-asserted-by":"crossref","first-page":"e000457","DOI":"10.1136\/esmoopen-2018-000457","article-title":"Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"4","author":"Fuc\u00e0","year":"2019","journal-title":"ESMO Open"},{"key":"R13-20240903","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2133.2008.08591.x","article-title":"Management of primary cicatricial alopecias:Options for treatment","volume":"159","author":"Harries","year":"2008","journal-title":"Br J Dermatol"},{"key":"R14-20240903","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s10067-019-04451-2","article-title":"Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis","volume":"38","author":"Roberts","year":"2019","journal-title":"Clin Rheumatol"}],"container-title":["International Journal of Trichology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijt.ijt_95_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:52:46Z","timestamp":1787763166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijt.ijt_95_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijt.ijt_95_21","relation":{},"ISSN":["0974-7753","0974-9241"],"issn-type":[{"value":"0974-7753","type":"print"},{"value":"0974-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"2021-09-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}